Molecular therapies research group - TERAMOL

Reference of the Group:

GIUV2015-253

 
Description of research activity:

The Research Group on Molecular Therapies is made up of basic and clinical researchers from the Universitat de València, the La Fe University Hospital, the University Clinical Hospital of Valencia, the University Hospital of the Ribera, the National Cancer Research Centre and the Prince Felipe Research Centre. The multidisciplinary composition of this group, which includes experts in molecular biology, bioinformatics and computational biology, medical oncology, surgery, pathology and new high-throughput technologies (genomics, transcriptomics, proteomics and metabolomics), allows the molecular complexity inherent to human diseases and the search for new therapies from an integrative and translational perspective. This approach is being applied in the different lines of research developed by the group, such as the identification of new biomarkers and molecular targets for the treatment of lung cancer, the physiopathology of pulmonary fibrosis, or the prevention and therapy of hypoxic-ischaemic neuropathies.

 
Web:
 
Scientific-technical goals:
  • Nuevas terapias dirigidas contra dianas moleculares en el adenocarcinoma pulmonar
  • Nuevas terapias dirigidas contra la fibrosis pulmonar
  • Nuevas terapias basadas en polifenoles naturales
 
Research lines:
  • New targeted therapies in lung cancer.Functional genomics of lung cancer. Identification of new markers and molecular targets for the treatment of lung cancer using omics technologies (transcriptomics, proteomics, metabolomics). Study of the mechanisms of innate and acquired resistance to tyrosine kinase inhibitors based on the epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Regulation of tumour metabolism by oncogenes and suppressor genes in lung cancer.
  • New targeted therapies in pulmonary fibrosis.Identification of new markers and molecular targets for the treatment of pulmonary fibrosis. Identification of molecular determinants of fibroblast-myofibroblast transition using omics technologies. Role of inflammation and stroma in the tumour microenvironment and lung cancer progression.
  • New therapies based on natural polyphenols.Identification of new markers associated with oxidative metabolism by mass spectrometry. Study of pathologies associated with oxidative stress and tissue hypoxia. Cellular and molecular mechanisms of the prevention of tissue damage in hypoxic-ischaemic neuropathies by means of natural and synthetic polyphenols.
 
Group members:
Name Nature of participation Entity Description
JULIAN CARRETERO ASUNCIONDirectorUniversitat de València
Research team
MIGUEL ANGEL ASENSI MIRALLESMemberUniversitat de València
JAVIER PEREDA CERVERAMemberUniversitat de València
JOSE MARCELO GALBIS CARAVAJALCollaboratorHospital de la Riberaresearcher
FATIMA AL-SHAHROUR NUÑEZCollaboratorFundacion Centro Nacional de Investigaciones Oncologicas Carlos Iiiresearcher
ROSA FARRAS RIVERACollaboratorFundación Centro de Investigación Príncipe Feliperesearcher
AGUSTIN LAHOZ RODRIGUEZCollaboratornullpostdoctoral researcher
 
CNAE:
  • -
 
Associated structure:
  • Physiology
 
Keywords:
  • Cáncer, pulmón, terapias dirigidas, tecnologías ómicas, EMT, CSC
  • Fibrosis, miofibroblasto, cáncer, estroma, inflamación
  • Metabolismo, Hipoxia, polifenoles, estrés oxidativo